Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials
Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials The ASCO Post
Онкология
Исследования и наука
1636 материалов по теме, собраны автоматически из проверенных источников
Онкология
NeOnc Technologies Holdings Signs Abu Dhabi MoU to Advance Brain Cancer Research and Clinical Development
NeOnc Technologies Holdings Signs Abu Dhabi MoU to Advance Brain Cancer Research and Clinical Development Quiver Quantitative
Онкология
U.S. trial tests ivonescimab for advanced biliary tract cancer
U.S. trial tests ivonescimab for advanced biliary tract cancer Bioengineer.org
Онкология
Patient Safety First: How a CNS Bridges Oncology Research and the Bedside
Patient Safety First: How a CNS Bridges Oncology Research and the Bedside Oncology Nursing News
Онкология
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Investing News Network
Онкология
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research BioSpace
Онкология
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research BioSpace
Онкология
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer EurekAlert!
🎗️
Онкология
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter in
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter in The National Law Review
🎗️
Онкология
North Chicago startup gets $2.5M to study Zika virus-based brain cancer treatment
North Chicago startup gets $2.5M to study Zika virus-based brain cancer treatment Crain's Chicago Business
🎗️
Онкология
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Business Wire
Онкология
For distant-stage biliary cancer, estimated five-year survival is under 5%. Summit plans a drug-combination trial.
For distant-stage biliary cancer, estimated five-year survival is under 5%. Summit plans a drug-combination trial. Stock Titan
Онкология
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Yahoo Finance Australia
Онкология
VHIO celebrates 20 years of research making a real difference to people with cancer
VHIO celebrates 20 years of research making a real difference to people with cancer VHIO
Онкология
First DS1025 dose administered in international Phase 1 solid-tumor trial
First DS1025 dose administered in international Phase 1 solid-tumor trial Bioengineer.org
‹
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
›